alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                       2,145,905
<SECURITIES>                                         0
<RECEIVABLES>                                3,680,525
<ALLOWANCES>                                   180,718
<INVENTORY>                                          0
<CURRENT-ASSETS>                             6,578,842
<PP&E>                                      84,071,367
<DEPRECIATION>                              10,477,734
<TOTAL-ASSETS>                              94,586,312
<CURRENT-LIABILITIES>                        6,906,454
<BONDS>                                     59,045,114
<PREFERRED-MANDATORY>                       13,538,140
<PREFERRED>                                    239,251
<COMMON>                                       621,134
<OTHER-SE>                                  13,863,023
<TOTAL-LIABILITY-AND-EQUITY>                94,586,312
<SALES>                                      2,188,063
<TOTAL-REVENUES>                             2,188,063
<CGS>                                        1,524,838
<TOTAL-COSTS>                                2,120,124
<OTHER-EXPENSES>                               866,914
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,882,992
<INCOME-PRETAX>                            (3,503,032)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (3,503,032)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,503,032)
<EPS-BASIC>                                     (0.07)
<EPS-DILUTED>                                   (0.07)


</TABLE>
No. 10-11159.

#### Louis David Johnson, Jr., Petitioner v. Chad Charles, et al.

565 U.S. 1077, 132 S. Ct. 836,

181 L. Ed. 2d 524,

2011 U.S. LEXIS 8780.

December 5, 2011.

Motion of petitioner for reconsideration of order denying leave to proceed in forma pauperis denied.
No. D-2615.

#### In the Matter of Discipline of Richard T. Cotter.

565 U.S. 1054, 132 S. Ct. 811,

181 L. Ed. 2d 522,

2011 U.S. LEXIS 8451.

November 28, 2011.

Richard T. Cotter, of Fort Myers Beach, Florida, is suspended from the practice of law in this Court and a rule will issue, returnable within 40 days, requiring him to show cause why he should not be disbarred from the practice of law in this Court.
page 1 of 1

Final December 18, 2020

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Center forDiseaseControlandPrevention 

Atlanta, Georgia30329

December 19 and 20, 2020

Friday,December19,2020

Time AGENDA ITEM PRESIDER PRESENTER(s)

11:00 Welcome &Introductions Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

11:15 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

mRNA-1273 Development Program

n/a

12:30 Break n/a

12:45 GRADE: Moderna COVID-19 vaccine

Evidence to Recommendation Framework: Moderna COVID-19 vaccine

Dr. Julia Gargano (CDC/NCIRD) Dr. Sara Oliver (CDC/NCIRD)

2:15 Break n/a

2:30 Public Comment n/a

3:00 Update on COVID-19 vaccines and Anaphylaxis

Clinical Considerations for use of mRNA COVID-19 vaccines

Dr. Tom Clark (CDC/NCIRD)

Dr. Sarah Mbaeyi (CDC/NCIRD)

4:15 Break

4:30 VOTE

Moderna COVID-19 Vaccine

Dr. Sara Oliver (CDC/NCIRD)

5:00 Adjourn n/a

Sunday, December 20, 2020

Time AGENDA ITEM PRESID ER PR ESENT ER(s)

11:00 Welcome &Introductions Dr. José Romero (ACIP Chair) 

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

11:30 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

Allocation of initial supplies of COVID-19 vaccine: Phase 1b and 1c

Discussion

Dr. Beth Bell (ACIP, WG Chair)

Dr. Kathleen Dooling (CDC/NCIRD)

2:45 Break n/a

3:00 Public Comment n/a

4:00 VOTE

Allocation of initial supplies of COVID-19 vaccine: Phase 1b and 1c Dr. Kathleen Dooling (CDC/NCIRD)

4:30 Adjourn n/a

Acronyms Definition

CDC Centers for Disease Control and Prevention

CMS Centers for Medicare and Medicaid Services

COVID-19 Coronavirus disease 2019

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NIAID National Institute of Allergy and Infectious Diseases

OIDP Office of Infectious Disease and HIV/AIDS Policy

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization

VE Vaccine Effectiveness
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

May 20, 2015

Order 

May 20, 2015

148898-9(116)

JEANNE HARRISON,

Plaintiff-Appellee,

v

MUNSON HEALTHCARE, INC.,

Defendant-Appellant,

and

SURGICAL ASSOCIATES OF TRAVERSE CITY, 

P.L.L.C., WILLIAM P. POTTHOFF, M.D., and 

CINDY GILLIAND, R.N.,

Defendants,

and

THOMAS R. HALL,

Appellee.

SC: 148898-9

COA: 304512, 304539

Grand Traverse CC: 

2009-027611-NH

__________________________________________/

On order of the Chief Justice, the motion of defendant-appellant for leave to file a 

supplemental brief in support of the application for leave to appeal is GRANTED. The 

supplemental brief submitted on May 12, 2015, is accepted for filing.
ARMED SERVICES BOARD OF CONTRACT APPEALS 

Appeals of -- ) 

) 

VLOX, LLC ) 

) 

) 

Under Contract No. W91B4N-09-D-5005 ) 

APPEARANCES FOR THE APPELLANT: 

APPEARANCES FOR THE GOVERNMENT: 

ASBCA Nos. 59305, 59306, 59307 

59308,59309,59310 

Joseph A. Artabane, Esq. 

Artabane & Belden, P.C. 

Washington, DC 

Billy B. Ruhling, II, Esq. 

DiMuroGinsberg, P.C. 

Alexandria, VA 

Raymond M. Saunders, Esq. 

Army Chief Trial Attorney 

Frank A. March, Esq. 

Trial Attorney 

ORDER OF DISMISSAL 

The dispute has been settled. The appeals are dismissed with prejudice. 

Dated: 8 March 2016 

~~ Administrative Judge 

Armed Services Board 

of Contract Appeals 
I certify that the foregoing is a true copy of the Order of Dismissal of the 

Armed Services Board of Contract Appeals in ASBCA Nos. 59305, 59306, 59307, 

59308, 59309, 59310, Appeals ofVLOX, LLC, rendered in conformance with the 

Board's Charter. 

Dated: 

2 

JEFFREY D. GARDIN 

Recorder, Armed Services 

Board of Contract Appeals
No. 11-5898.

#### Victor B. White, Petitioner v. FNU Smereka, et al.

565 U.S. 966, 132 S. Ct. 460,

181 L. Ed. 2d 299,

2011 U.S. LEXIS 7558.

October 17, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 410 Fed. Appx. 714.
122

Section C: Recommended Funding Levels, by State

Utah

Program Intervention Budgets: 2014

Recommended Annual Investment $19.3 million

Deaths in State Caused by Smoking

Annual average smoking-attributable deaths 1,300

Youth aged 0-17 projected to die from smoking 38,600

Annual Costs Incurred in State from Smoking

Total medical $542 million

State Revenue from Tobacco Sales and Settlement

FY 2012 tobacco tax revenue $132.0 million

FY 2012 tobacco settlement payment $36.4 million

Total state revenue from tobacco sales and settlement $168.4 million

Percent Tobacco Revenue to Fund at Recommended Level 11%

Annual Total (Millions) Annual Per Capita

Minimum Recommended Minimum Recommended

I. State and Community Interventions 

Multiple social resources working together will 

have the greatest long-term population impact.

$5.8 $7.3 $2.03 $2.56

II. Mass-Reach Health Communication Interventions 

Media interventions work to prevent smoking initiation, 

promote cessation, and shape social norms.

$2.3 $3.4 $0.81 $1.19

III. Cessation Interventions 

Tobacco use treatment is effective and highly cost-effective. $4.0 $6.1 $1.40 $2.14

IV. Surveillance and Evaluation 

Publicly funded programs should be accountable and 

demonstrate effectiveness.

$1.2 $1.7 $0.42 $0.59

V. Infrastructure, Administration, and Management 

Complex, integrated programs require experienced 

staff to provide fiscal management, accountability, 

and coordination.

$0.6 $0.8 $0.21 $0.29

TOTAL $13.9 $19.3 $4.87 $6.77

Note: A justification for each program element and the rationale for the budget estimates are provided in Section A. The funding estimates presented are based on adjustments for changes in population and cost-of-living increases since Best Practices—2007 was published. The actual 

funding required for implementing programs will vary depending on state characteristics, such as prevalence of tobacco use, sociodemographic 

factors, and other factors. See Appendix E for data sources on deaths, costs, revenue, and state-specific factors. 

Centers for Disease Control and Prevention • Office on Smoking and Health

www.cdc.gov/tobacco • tobaccoinfo@cdc.gov • 1 (800) CDC-INFO or 1 (800) 232-4636 

2014
No. 10-397.

#### Heathcliffe John Bradley, Petitioner v. Eric H. Holder, Jr., Attorney General.

562 U.S. 1135, 131 S. Ct. 906,

178 L. Ed. 2d 749,

2011 U.S. LEXIS 478.

January 10, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.

Same case below, 603 F.3d 235.
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
</LEGEND>
<CIK>                         0001066850
<NAME>                        Innovative Holdings & Technologies, Inc.
<MULTIPLIER>                                   1
<CURRENCY>                                     US DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   MAR-31-2000
<EXCHANGE-RATE>                                          1
<CASH>                                                 616
<SECURITIES>                                             0
<RECEIVABLES>                                       10,250
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                    14,547
<PP&E>                                              20,795
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                      40,923
<CURRENT-LIABILITIES>                              345,791
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                           (2,313)
<OTHER-SE>                                       (304,869)
<TOTAL-LIABILITY-AND-EQUITY>                       40,523
<SALES>                                                 0
<TOTAL-REVENUES>                                        0
<CGS>                                                   0
<TOTAL-COSTS>                                           0
<OTHER-EXPENSES>                                   89,610
<LOSS-PROVISION>                                        0
<INTEREST-EXPENSE>                                    758
<INCOME-PRETAX>                                         0
<INCOME-TAX>                                            0
<INCOME-CONTINUING>                                     0
<DISCONTINUED>                                          0
<EXTRAORDINARY>                                         0
<CHANGES>                                               0
<NET-INCOME>                                      (90,368)
<EPS-BASIC>                                       (0.0039)
<EPS-DILUTED>                                     (0.0039)




</TABLE>
**DoD 4000.25-2-M**

*DLM 4000.25, Volume 2, November 26, 2019*

*Change 13*

**AP3.7. APPENDIX 3.7**

**SINGLE MANAGED CONVENTIONAL AMMUNITION FREEZE/UNFREEZE ACTION**

## 

**AP3.7-**

AP3.7-1

APPENDIX 3.7
≥95% (24 awardees)

75% - 94% (19 awardees)

50% - 74% (8 awardees)

25% - 49% (1 awardee)

<25% (1 awardee)

No IIS (1 awardee)

No data (2 awardees)

Percentage of children aged < 6 years participating in an immunization 

information system -- United States, five cities§, and D.C., 2013

National Participation: 90% (excluding Territories)

Source: CY2013 IISAR

§ Chicago, IL; Houston, TX; New York City, NY; Philadelphia, PA; San Antonio, TX.
Appendix B

Appendix B-1

B

Appendix B: Vaccines

United States Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-

Vaccine Excipient Table . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-

Latex in Vaccine Packaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1

Vaccine-Preventable Disease Terms in Multiple Languages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1

Resources for Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1
I 

116TH CONGRESS 

1ST SESSION H. R. 3430 

To amend title XVIII of the Social Security Act to extend funding for 

quality measure endorsement, input, and selection under the Medicare 

program. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 24, 2019 

Ms. JUDY CHU of California (for herself and Mr. SCHWEIKERT) introduced 

the following bill; which was referred to the Committee on Ways and 

Means, and in addition to the Committee on Energy and Commerce, for 

a period to be subsequently determined by the Speaker, in each case for 

consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to extend 

funding for quality measure endorsement, input, and selection under the Medicare program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. EXTENSION OF FUNDING FOR QUALITY MEAS4 URE ENDORSEMENT, INPUT, AND SELECTION 

5 UNDER MEDICARE PROGRAM. 

6 (a) IN GENERAL.—Section 1890(d)(2) of the Social 

7 Security Act (42 U.S.C. 1395aaa(d)(2)) is amended— 


kjohnson on DSK79L0C42 with BILLS
2 

•HR 3430 IH

1 (1) by striking ‘‘and $7,500,000’’ and inserting 

2 ‘‘$7,500,000’’; and 

3 (2) by striking ‘‘and 2019.’’ and inserting ‘‘and 

4 2019, and $30,000,000 for each of fiscal years 2020 

5 through 2022.’’. 

6 (b) INPUT FOR REMOVAL OF MEASURES.—Section 

7 1890(b) of the Social Security Act (42 U.S.C. 1395aaa(b)) 

8 is amended by inserting after paragraph (3) the following: 

9 ‘‘(4) REMOVAL OF MEASURES.—The entity may 

10 provide input to the Secretary on quality and effi11 ciency measures described in paragraph (7)(B) that 

12 could be considered for removal.’’. 

13 (c) PRIORITIZATION OF MEASURE ENDORSEMENT.— 

14 Section 1890(b) of the Social Security Act (42 U.S.C. 

15 1395aaa(b)) is amended by adding at the end the fol16 lowing: 

17 ‘‘(9) PRIORITIZATION OF MEASURE ENDORSE18 MENT.—The Secretary— 

19 ‘‘(A) during the period beginning on the 

20 date of the enactment of this paragraph and 

21 ending on December 31, 2023, shall prioritize 

22 the endorsement of measures relating to mater23 nal morbidity and mortality by the entity with 

24 a contract under subsection (a) in connection 


kjohnson on DSK79L0C42 with BILLS
3 

•HR 3430 IH

1 with endorsement of measures described in 

2 paragraph (2); 

3 ‘‘(B) on and after January 1, 2024, may 

4 prioritize the endorsement of such measures by 

5 such entity.’’. 

Æ 


kjohnson on DSK79L0C42 with BILLS
≥95% (7 awardees)

75% - 94% (25 awardees)

50% - 74% (12 awardees)

25% - 49% (5 awardees)

<25% (7 awardees)

No IIS (0 awardees)

No data (0 awardees)

Percentage of adults aged ≥19 years participating in an immunization 

information system -- United States, five cities§, and D.C., 2020

National Participation: 68% (excluding Territories)

Source: CY2020 IISAR

§ Chicago, IL; Houston, TX; New York City, NY; Philadelphia, PA; San Antonio, TX.
EPA Improving Environmental Regulations

Public Meeting Summary 

March 21, 2011

EPA Region 1

Boston, MA

Plenary Summary/Open Comment Period

Purpose

 “This listening session arises out of a recent executive order for Improving 

Regulations and Regulatory Review, more formally known as Executive Order 

13563, issued by President Obama Opening Presentation. It is intended to be an 

informal, non-adversarial listening session providing interested parties with the 

opportunity to make comments - both orally and in writing comments pursuant to 

the Executive Order”

Regional Administrator Curt Spalding – Opening remarks attached

Matt Hoagland – Moderator – Remarks attached

Comments Received During Focused Comment Period 

Region 1 did not hold a Focused Comment Period 

Comments Received During Open Comment Period

Transcript Attached 

Summary of Attendees

Excel Spreadsheet Attached 

Sample Table of Participants

Region 1 did not hold any breakout sessions
No. 11-6988.

#### Bryant R. Filter, Petitioner v. United States.

565 U.S. 1070, 132 S. Ct. 787,

181 L. Ed. 2d 503,

2011 U.S. LEXIS 8384.

November 28, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
Exhibit 35.4

Annual Statement as to Compliance For the Year Ended December 31, 2019

Citigroup Commercial Mortgage Securities Inc., Series 2017-CD5

Pursuant to Section 3.01 (37) of the Subservicing Agreement governing the referenced transaction (the “Servicing Agreement”), I hereby attest that:

|   | i. | A review of the activities and performance of Berkadia as Subservicer during the period has been made under my supervision. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------|

|   | ii. | To the best of my knowledge, based on such review, Berkadia as Subservicer has fulfilled, in all material respects, its obligations under this Subservicing Agreement throughout the period and no default by the Subservicer under the Subservicing Agreement has occurred and is continuing. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Berkadia,

Mark E. McCool President

February 10, 2020

Inv. 228 Lib. A
ID Descriptor L* a* b* c h dL* da* db* dEcmc*

Standard 3921 STANDARD 48.95 1.01 12.46

Tolerance

1 3921A BLUE-GREEN 

LIMIT 50.81 0.68 11.79 1.86 -0.33 -0.67 1.07

2

3

4

5

6

7

8

9

Shade Number TAN 499 Piece/Roll Number 3921

DLA/ARMY SHADE TOLERANCE PROJECT May 14, 2018

Fabric Nomenclature SLACKS, MATERNITY, WORK UNIFORM, 

91% NYLON MIL-S-44410

COMMENTS: NUMBERS ARE FOR REFERENCE ONLY 

Equipment Type HUNTER ULTRA SCAN PRO Setting Mode: Specular Included - 

Reflectance

UV Filter – OUT UV Lamp OFF
JOSEPHINE M. BATTAGLIA 

Is inducted into the Defense Personnel Support Center Hall of Fame this sixteenth day of June 1995 

for her extraordinary assistance and support as Secretary to the Commander – and for her 

continuous outstanding mission support throughout her tenure at DPSC – from 1955 to 1994. Ms. 

Battaglia’s dedication and outstanding performance was continuous in one of the most visible 

positions at DPSC. Maintaining the hectic pace of the position, she consistently and tirelessly 

produced professional results. She continually demonstrated exceptional knowledge of her everchanging job – and of the Center’s diverse mission. She was a keystone in maintaining the smooth 

transitions and operations among the 11 DPSC commanders with whom she served, and 

exemplified the highest professional example throughout the Command Group and organization. 

Hall of Fame Inductees Page 1 of 1

https://www.troopsupport.dla.mil/about_us/battagli.htm 1/27/2016
k

-IP( I5

I

w’S?.c/f/ I;

jjids,L

.hc

\íij ! “i

‘17d’S QX1’

4,

1

2f,t t

41

i4’ OLq

ioJ

d.

7cLX’

DAi’i - /
C 55—.,’ • _•% 5S.:.•:

•-. \r-.

55%55, •—.•‘:: -

--

•

<EZ. LJ

c.

5?

cI-. ‘%_

5

Th

‘çz

cj

L

1’

C

cfL r s—

iS
<PAGE>

                                  Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of theglobe.com  (the "Company") on Form
10-QSB for the period ending  September  30, 2003, as filed with the  Securities
and Exchange  Commission on the date hereof (the "Report"),  I, Michael S. Egan,
Chief Executive Officer of the Company,  certify,  pursuant to 18 U.S.C. Section
1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.

Date: November 14, 2003


/s/ Michael S. Egan
-----------------------
Michael S. Egan
Chief Executive Officer





                                       38